Log in

Relevant bibliographies by topics / Dermatological Immunotherapy

Contents

Journal articles
Book chapters

Academic literature on the topic 'Dermatological Immunotherapy'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Dermatological Immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Dermatological Immunotherapy"

1

Rigel, Darrell, and Brian Berman. "1. Introduction: Immunotherapy for Dermatological Conditions." Acta Dermato-Venereologica 83 (January 1, 2003): 5–7. http://dx.doi.org/10.1080/03658340310011870.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rigel B and B. Berman. "1. Introduction: Immunotherapy for Dermatological Conditions." Acta Dermato-Venereologica 83 (September 1, 2003): 5–7. http://dx.doi.org/10.1080/00015555-832142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Zayad, Anas, Maira A. Bhatty, Maheen Ahmad, and Faiz Anwer. "Dermatological adverse events linked to talquetamab immunotherapy in multiple myeloma." BMJ Case Reports 17, no. 11 (2024): e260751. http://dx.doi.org/10.1136/bcr-2024-260751.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Fane, Lauren S., Jimmy T. Efird, Charulata Jindal, and Tithi Biswas. "Dermatological Autoimmune Considerations of Immune Checkpoint Therapy." Biomedicines 10, no. 10 (2022): 2339. http://dx.doi.org/10.3390/biomedicines10102339.

Full text

Abstract:

The most common immune-related adverse events (irAEs) involve the skin, and several serve as predictors of response to immune checkpoint inhibitor (ICI) therapy, especially in melanoma. Patients with pre-existing skin autoimmune diseases (ADs) have been excluded from ICI studies for safety concerns, yet recent research has shown that dermatological ADs can be managed without discontinuing ICI therapy. Patients with ADs respond as well or better to ICIs and can be included as candidates in clinical trials. Frequently taken during ICI therapy, steroids impair immunotherapy efficacy in certain an

APA, Harvard, Vancouver, ISO, and other styles

5

Salloum, Antoine, Maya Habre, Joanna Abi Chebl, et al. "Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review." Immunotherapy 14, no. 6 (2022): 489–503. http://dx.doi.org/10.2217/imt-2021-0244.

Full text

Abstract:

Aim: This paper presents the reported dermatological adverse events (AEs) associated with approved combinations of immunotherapy with drugs of the same class, or in combination with targeted therapy or chemotherapy. Materials & methods: PubMed was used as an electronic database, and a total of 29 articles were reviewed which reported dermatological AEs following combination therapies with nivolumab, ipilimumab, axitinib, pembrolizumab, lenvatinib, avelumab, atezolizumab, carboplatin, etoposide, paclitaxel, bevacizumab, pemetrexed, cisplatin and durvalumab. Results: The dermatological AEs r

APA, Harvard, Vancouver, ISO, and other styles

6

Polonskaia, Aleksandra S., Evgeniya A. Shatokhina, and Larisa S. Kruglova. "Balneotherapy as a promising method for the correction of dermatologic adverse events of cancer therapy." Russian Journal of Physiotherapy, Balneology and Rehabilitation 20, no. 6 (2022): 551–58. http://dx.doi.org/10.17816/rjpbr108026.

Full text

Abstract:

Cancer treatment with chemotherapy, targeted and immunotherapy is associated with a wide spectrum of dermatologic adverse events. Xerosis (dryness) of the skin is the most prevalent skin side effect in oncologic patients, which occurs both during treatment with "classic" chemotherapy drugs and modern cancer drugs, such as targeted therapy and immunotherapy. Despite the high prevalence of this side effect, current approaches to the correction of skin xerosis in cancer patients are very limited. At the same time, in the absence of adequate supportive treatment of xerosis, the formation of

APA, Harvard, Vancouver, ISO, and other styles

7

Mazumder, Anika, Kavita Darji, Kristin Smith, and Mary Guo. "Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors." BMJ Case Reports 15, no. 12 (2022): e253059. http://dx.doi.org/10.1136/bcr-2022-253059.

Full text

Abstract:

Bullous pemphigoid is a rare and severe adverse reaction to immune-checkpoint inhibitors that can be life-threatening. Here, we present two cases of bullous pemphigoid secondary to nivolumab and ipilimumab+nivolumab therapy, respectively. Both cases presented months after discontinuation of immunotherapy. Our first case highlights the life-threatening nature of bullous pemphigoid due to its potential to cause laryngeal oedema. Our second case illustrates that cytotoxic T-lymphocyte-associated protein-4 inhibitors can rarely lead to bullous pemphigoid, in addition to programmed cell death-1 (PD

APA, Harvard, Vancouver, ISO, and other styles

8

Pires, Mario Cezar, João Mauricio Martins, F. Montealegre, and Flávia Romero Gatti. "Vitiligo after Diphencyprone for Alopecia Areata." Dermatology Research and Practice 2010 (2010): 1–2. http://dx.doi.org/10.1155/2010/171265.

Full text

Abstract:

The topical immunotherapy is used to treat alopecia areata and recalcitrant warts since the 1970s. Diphencyprone is a contact sensitizer used to treat dermatological conditions resulting from as altered immunological state, such as extensive alopecia areata, being partially effective and safe. Side effects include local eczema with blistering, regional lymphadenopathy and contact urticaria. Rare adverse effects include an erythema multiforme-like reaction, hyperpigmenttion, hypopigmentation, and vitiligo. We report a 30-year-old, Brazilian male who developed vitiligo lesions following DPCP the

APA, Harvard, Vancouver, ISO, and other styles

9

Kucharczyk, Emilia, Karolina Pawłuszkiewicz, Karol Biliński, Joanna Maj, and Małgorzata Ponikowska. "Intralesional Immunotherapy for Non-Genital Viral Warts: A Review of Current Evidence and Future Perspectives." International Journal of Molecular Sciences 26, no. 12 (2025): 5644. https://doi.org/10.3390/ijms26125644.

Full text

Abstract:

Cutaneous warts caused by human papillomavirus (HPV) are among the most common dermatological conditions, affecting the quality of life of numerous people. Although they are widespread, effective and reliable treatment alternatives are limited, emphasizing the necessity for novel treatment options. Intralesional immunotherapy has emerged as a promising alternative, aiming to stimulate the host immune response to achieve the clearance of both treated and distant lesions. This review explores the immunopathogenesis of cutaneous warts and provides an in-depth analysis of intralesional therapies i

APA, Harvard, Vancouver, ISO, and other styles

10

Rovers, Jessica F. J., and H. Jorn Bovenschen. "Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer." International Journal of Dermatology 59, no. 12 (2020): 1485–90. http://dx.doi.org/10.1111/ijd.15163.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Dermatological Immunotherapy"

1

Pectasides, Eirini, and Helen Gogas. "Immunotherapy for Melanoma." In European Handbook of Dermatological Treatments. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-15130-9_150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wu, Jennifer, and Mario E. Lacouture. "Dermatologic Toxicities." In SITC’s Guide to Managing Immunotherapy Toxicity. Springer Publishing Company, 2019. http://dx.doi.org/10.1891/9780826172150.0005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Patil, Pradnya D., and Vamsidhar Velcheti. "Dermatologic Toxicities of Immunotherapy." In Handbook of Cancer Treatment-Related Symptons and Toxicities. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-323-67241-2.00022-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Reddy, Bhavanam Sudhakara, Sirigireddy Sivajothi, and Kambala Swetha. "Prevention and Control Strategy." In Common Ear Diseases in Dogs: Diagnosis and Management. BENTHAM SCIENCE PUBLISHERS, 2025. https://doi.org/10.2174/9789815313598125010026.

Full text

Abstract:

Ear diseases are considered as one of the common disorders in small animal practice and the number one cause for veterinary visits among dog owners. Commonly reported clinical signs in dogs with ear disease were scratching or pawing at the ear, otitis, head tilting, head shaking, strong and unpleasant odour from the ears, abnormal ear discharges and pain evincing while palpation of ears. These ear infections can cause significant discomfort to the dogs as well as occurrence of recurrence. The first step in the control and prevention of ear infections is to identify the primary and/ or perpetua

APA, Harvard, Vancouver, ISO, and other styles

5

Baker, Mary Grace, and Julie Wang. "Oral, sublingual, and dermatologic immunotherapy for food allergy." In Allergic and Immunologic Diseases. Elsevier, 2022. http://dx.doi.org/10.1016/b978-0-323-95061-9.00037-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!